Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $11.00 price target on CVRx Inc (NASDAQ: CVRX).

The analyst commented, "On 8/4, CVRx (CVRX, OW) reported 2Q25 operating results and tightened CY25 revenue guidance. Specifically, CVRX reported revenue of $13.6 million (Cantor $13.0 million / FactSet consensus $13.3 million, representing YoY growth of ~15%, driven by U.S. Heart Failure revenue of $12.1 million, which represents YoY growth of ~15%. The company had 240 active implanting centers at the end of the quarter, up 13 sequentially. We are encouraged by CVRX's improvement in the number of implanting centers and commentary around a more stabilized salesforce. Moreover, with recent reimbursement wins and the move to a CPT 1 Code in January, we believe CVRX is positioned well to drive adoption and revenue growth in 2026."

For an analyst ratings summary and ratings history on CVRx Inc click here. For more ratings news on CVRx Inc click here.

Shares of CVRx Inc closed at $7.24 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Full Circle Lithium closes $5.14M private placement